Equities
Health CareHealth Care Providers
  • Price (EUR)37.00
  • Today's Change-1.75 / -4.52%
  • Shares traded11.01k
  • 1 Year change-1.33%
  • Beta0.7989
Data delayed at least 15 minutes, as of Feb 11 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Equasens SA is formerly known as Pharmagest Interactive SA is a France-based company. The Company is engaged in publishing and integration of software packages intended for pharmacies, hospitals, health establishments, laboratories, retirement homes and health professionals. Its activity is distributed in publishing and integration of software packages for pharmacies, publishing of IT solutions for health and medico-social establishments and development of solutions and infrastructure for e-Health. It provides software packages for managing databases, information, stocks, orders, electronic care sheets, etc. It offers publishing and integration of software packages for retirement homes, hospitals and care homes (software for managing admissions, invoicing, tracking collections and accounting, care monitoring, stewardship management, etc.);

  • Revenue in EUR (TTM)224.73m
  • Net income in EUR36.31m
  • Incorporated1996
  • Employees1.42k
  • Location
    Equasens SA5 Allee de Saint-CloudVILLERS LES NANCY 54600FranceFRA
  • Phone+33 383159595
  • Fax+33 383159805
  • Websitehttps://equasens.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EQS:PAR since
announced
Transaction
value
Erevo SASAnnounced05 Jan 202605 Jan 2026Announced-17.50%--
Data delayed at least 15 minutes, as of Feb 11 2026 16:35 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cheops Technology France SA-100.00bn-100.00bn133.40m296.00------------------------------------------------168.41---41.53------
Capital B SA12.17m-1.88m136.29m125.00--1.55--11.20-0.014-0.0140.10640.38790.1063--3.0990,125.93-1.64-16.58-1.70-23.3051.6653.39-15.46-35.16---35.020.7054---32.0743.44106.4144.8066.24--
Consort NT SA-100.00bn-100.00bn140.53m1.86k--------------------------12.44--33.53--86.74--5.43------61.2712.505.8412.4614.993.96-2.09
Keyrus SA346.70m14.84m141.33m2.67k8.842.117.040.40770.92520.925221.693.871.0716,377.754.52114,648.103.731.147.692.5662.2164.653.471.151.022.190.5889---4.254.34-77.47---9.13--
Infotel SA292.19m15.40m265.90m2.03k16.972.3211.240.912.232.2342.2716.271.25--4.81159,929.405.706.759.4811.8899.8299.894.555.89----0.225279.00-4.143.492.287.41-0.573813.75
Sword Group SE341.94m20.48m326.44m2.41k15.774.9610.950.95472.172.1736.226.891.240.578.16150,435.107.3918.3811.2926.5089.0991.925.9717.271.25--0.596287.1312.118.67-4.4410.56-11.92--
Quadient SA1.08bn61.90m534.96m4.80k8.670.48943.300.49741.791.8231.0031.720.42183.665.81224,130.002.442.083.362.7374.6873.465.795.591.053.920.438638.122.84-0.8927-19.3066.48-0.257514.87
Equasens SA224.73m36.31m588.00m1.42k16.202.5310.992.622.392.3914.8115.300.55136.124.76158,709.809.1312.2013.6317.3368.8168.7716.5720.411.20--0.132242.60-1.386.45-22.996.05-7.306.79
Aubay SA537.04m34.79m686.60m7.47k19.712.5016.081.282.732.7341.9121.551.15190.373.3671,768.547.467.8811.9013.0075.8477.046.486.731.76--0.067738.841.165.2812.687.35-0.62716.72
Lectra SA515.56m27.91m873.94m3.00k31.322.6412.411.700.73760.737613.648.740.61252.275.81171,852.303.174.454.866.4572.6269.625.187.070.61484.940.255946.9010.2813.47-8.081.24-11.390.00
Atos SE8.63bn1.49bn945.39m66.97k0.018--0.50130.10952,710.382,710.38888.80-4.751.0810.823.54110,520.8018.64-8.7052.49-15.0276.3172.6917.31-12.351.420.39881.03---10.44-3.74107.21-9.706.50--
Neurones SA832.18m50.74m952.47m7.19k18.792.5712.061.142.082.0834.1815.261.190.54834.64117,423.708.708.3115.2813.8399.9399.917.317.572.31--0.087774.489.339.706.3711.288.8245.41
Data as of Feb 11 2026. Currency figures normalised to Equasens SA's reporting currency: Euro EUR

Institutional shareholders

8.31%Per cent of shares held by top holders
HolderShares% Held
Amundi Asset Management SASU (Investment Management)as of 07 Jan 2026279.24k1.84%
The Vanguard Group, Inc.as of 07 Jan 2026187.26k1.23%
DNCA Finance SAas of 30 Jun 2025177.61k1.17%
Danske Bank A/S (Investment Management)as of 31 Jan 2026160.42k1.06%
Cr�dit Mutuel Asset Management SAas of 30 Oct 2025135.20k0.89%
Capricorn Partners NV (Investment Management)as of 31 Dec 202592.76k0.61%
Financi�re de l'�chiquier SAas of 31 Mar 202568.08k0.45%
CPR Asset Management SAas of 31 Dec 202555.95k0.37%
BlackRock Fund Advisorsas of 08 Jan 202653.23k0.35%
Gay-Lussac Gestion SAas of 31 Dec 202450.50k0.33%
More ▼
Data from 31 Dec 2024 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.